Dedicated to Research
Therapeutic agents being developed by Anapneo to treat sleep apnea are currently in advanced preclinical development. Anapneo welcomes inquiries from investment groups or others who may be interested in leading or participating in a Series A investment to support Phase I and Phase II clinical trials of our lead compounds.
Interested parties are requested to contact Anapneo Therapeutics using the Contact Us
University of Chicago
IIT Research Institute